Cardiovascular Effects of Doxepin
Doxepin causes orthostatic hypotension and modest increases in heart rate, with minimal direct effects on blood pressure in the supine position, but can significantly impair orthostatic blood pressure regulation.
Blood Pressure Effects
Doxepin's impact on blood pressure is primarily characterized by orthostatic hypotension rather than sustained hypertension or hypotension. The FDA labeling explicitly lists "severe hypotension" as a critical manifestation of toxicity, particularly in overdose situations 1.
In therapeutic dosing:
- At doses ≤150 mg/day: Doxepin does not appreciably antagonize antihypertensive medications like guanethidine 1
- At doses >150 mg/day: May block the antihypertensive effect of guanethidine and related compounds 1
- Orthostatic changes: A study in 32 depressed patients with preexisting cardiac disease found doxepin caused a "significant increase in orthostatic hypotension," contributing to a 16% dropout rate due to cardiovascular side effects 2
The mechanism involves anticholinergic and adrenergic effects at synapses, preventing norepinephrine reuptake 1. At higher doses, norepinephrine response potentiation can occur in animals, though this effect was not demonstrated in humans 1.
Heart Rate Effects
Doxepin produces modest increases in heart rate (tachycardia), though the effect is less robust compared to other cardiovascular impacts:
- The FDA labeling lists "tachycardia" among adverse effects 1
- In patients with preexisting left ventricular impairment and cardiac disease, doxepin "did not have a robust effect on heart rate" 2
- A comparative study in elderly depressed patients showed "small but significant increases in heart rate" with doxepin 3
- Another study found a "slight increase in mean heart rate on effort" of 2-6 beats per minute, attributed to the cocaine-like effect of tricyclic drugs, though this was neither clinically nor statistically significant 4
Important Cardiac Conduction Effects
Beyond simple heart rate changes, doxepin affects cardiac conduction:
- Slows cardiac conduction and can cause PR interval prolongation 2, 3
- Decreases QRS interval (unlike some other tricyclics that prolong it) 3
- Has antiarrhythmic effects in some patients, particularly reducing premature ventricular contractions (PVCs) 2
- Does not prolong QTc interval even at supratherapeutic doses up to 50 mg in thorough QT studies 5
Clinical Implications and Monitoring
Key Cardiovascular Risks:
- Orthostatic hypotension is the primary blood pressure concern—monitor patients when standing, especially elderly patients
- Cardiac dysrhythmias can occur, particularly in overdose 1
- Conduction abnormalities including AV block may develop 6
Dosing Considerations:
- The cardiovascular profile is dose-dependent
- Maximum recommended once-daily dose is 150 mg to minimize cardiovascular effects 1
- In patients with cardiac disease, doxepin was poorly tolerated with a 41% overall dropout rate 2
Common Pitfall:
The longstanding belief that doxepin is the "safest" tricyclic for the heart is not supported by rigorous evidence. A 1991 study specifically addressing this question found that "doxepin afforded no greater margin of cardiovascular safety" compared to imipramine and nortriptyline in patients with heart disease 2. The drug's cardiovascular effects are comparable to other tricyclics, particularly regarding orthostatic hypotension.
Monitoring Recommendations:
- Baseline ECG in patients with cardiac risk factors or doses >100-120 mg/day
- Orthostatic vital signs, especially in elderly patients
- Watch for dizziness, syncope, or falls related to orthostatic changes
- In overdose: continuous cardiac monitoring for minimum 6 hours, with QRS width ≥0.10 seconds indicating severity 1